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Abstract: 5-Fluorouracil (5-FU) is used widely as an anticancer drug to treat solid cancers, 
such as colon, breast, rectal, and pancreatic cancers, although its clinical application is 
limited because 5-FU has gastrointestinal and hematological toxicity. Many groups are 
searching for prodrugs with functions that are tumor selective in their delivery and can be 
activated to improve the clinical utility of 5-FU as an important cancer chemotherapeutic 
agent. UV and ionizing radiation can cause chemical reactions in a localized area of the 
body, and these have been applied in the development of site-specific drug activation and 
sensitization. In this review, we describe recent progress in the development of novel 5-FU 
prodrugs that are activated site specifically by UV light and ionizing radiation in the tumor 
microenvironment. We also discuss the chemical mechanisms underlying this activation. 
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Introduction 
5-Fluorouracil (5-FU) is the first class of compounds that has been subjected to intensive research 
as a chemotherapeutic agent. Although 5-FU is a potent radiosensitizer in colon and rectal cancers, and 
acts in a similar manner as 5-bromouracil, its main biochemical action is as an antimetabolite of the 
uracil anabolic pathways [1, 2]. The cytotoxic effect of 5-FU in most systems is attributed primarily to 
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its anabolism to 5-fluoro-2′-deoxyuridine monophosphate (FdUMP), a potent inhibitor of thymidylate 
synthase [3, 4], a pivotal enzyme in pyrimidine biosynthesis [5-7]. Thymidylate synthase is a vital 
enzyme for the growth of tumors, and the expression of this gene is dependent on the cell cycle. 5-FU 
shows greater selectivity against solid tumors with multiresistance to drugs than do other antitumor 
agents. However, 5-FU is particularly toxic to dividing tissues, and its clinical use is limited by its 
severe side effects on normal cells. 
The term “prodrug”, first introduced by Albert, refers to a chemically modified form of a drug [8] 
that is devoid of pharmacological activity, but that can be converted to the active form of the drug in a 
biological system, where it exerts the desired action. This strategy can improve the limitations 
associated with the effective transport into tumor cells, catabolic inactivation before the cytotoxic 
entity can reach the tumor, and short plasma half-1ife [9-12]. The prodrug strategy for a site-specific or 
tumor-targeting delivery has been employed, and much effort has been expended in searching for 
prodrugs that might improve the clinical utility of 5-FU as an important cancer chemotherapeutic 
agent. Examples include (1) prodrug forms of 5-FU such as tegafur (Ftorafur) [1-(2-tetrahydro-
furanyl)-5-fluorouracil] derivatives [13-15], 1-alkylcarbamoyl-5-fluorouracils [16,17], 5-fluoro-2′-
deoxyuridine (5-FdUrd) derivatives [18, 19], and polymeric matrix systems for the controlled release 
of 5-FU [20-22]; (2) the recently advanced tumor-specific targeting of 5-FU prodrugs using tumor-
specific gene expression such as antibody-directed enzyme prodrug therapy [23-25] and targeting 
carcinoembryonic antigen-promoted activity [26, 27]; and (3) intratumoral prodrug activation in which 
a nontoxic drug is converted into 5-FU by intratumorally expressed enzymes [28, 29]. 
 
Most antitumor prodrugs including 5-FU have been designed to release the parent drug by either 
chemical hydrolysis or enzymatic hydrolysis. However, both processes have their drawbacks: chemical 
hydrolysis is not restricted to tumor tissue, and enzymatic release requires the identification of suitable 
tumor-specific enzymes or the targeted delivery of enzymes to the tumor tissue. To provide an 
alternative prodrug design for overcoming these problems, attention has focused on the external and 
nonenzymatic activation of prodrugs to achieve more direct control of drug release in a targeted area of 
the body. Among the various external triggers, ionizing radiation and UV-visible (UV-vis) light are 
particularly attractive because they can be controlled precisely in terms of the energy and irradiation 
site (Figure 1). The isolation and characterization of N1-C5′-linked pyrimidine dimer hydrates with a 
5-FU component has been reported [30, 31]. 5-FU dimer hydrates have also been identified as a new 
class of radiation-activated prodrugs that are not activated by enzymatic or spontaneous reaction 
processes and show no antitumor activity, but these prodrugs show selective toxicity against hypoxic 
tumor cells after the release of the antitumor agent of 5-FU by exposure to ionizing radiation under 
hypoxic conditions. Photoinduced activation of prodrugs is achieved by photocleavage of the 
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protecting groups in the prodrugs via direct absorption of UV-vis light. Although short-wavelength 
light does not penetrate through the human body, endoscopic delivery of light of a specific wavelength 
can activate this type of prodrug. In the current review, we summarize recent efforts to develop novel 
5-FU prodrugs that are activatable by external physical agents such as ionizing radiation and UV–vis 
light under tumor-specific conditions. 
Radiation-activatable 5-FU Prodrugs 
It is well known that various electrophilic compounds can enhance the sensitivity of hypoxic cells 
toward ionizing radiation [32, 33]. Because of the inefficient supply of oxygen to the core of tumor 
tissue by poorly developed blood vessels, hypoxic cells in the solid tumors are resistant to radiation 
therapy and may be likewise refractory to certain types of chemotherapeutic agents operative through a 
variety of mechanisms [34].  
Wide varieties of bioreduction-activatable prodrugs have been developed as anticancer agents [35-
37]. Bioreductive prodrugs can be activated into their radical intermediates, which are oxidized to the 
prodrug under aerobic conditions. However, under hypoxic conditions (e.g., in solid tumors), this 
oxidation is much slower and usually increases the levels of toxic radical intermediates, resulting in a 
solid tumor-selective therapy. In general, hypoxic cells in low oxygen tension regions are more 
resistant to treatment with radiotherapy and require a two- to three-fold higher radiation dose, 
indicating the importance of bioreductive drugs. 
Radiation generates high concentrations of molecular free radicals, hydrated electrons (eaq–), 
hydrogen atoms (•H) and hydroxyl radicals (•OH) in irradiated tissues [38]. Under aerobic conditions, 
hydrated electrons react with O2 to produce superoxide radical anion (O2–•) (Scheme 1). In contrast, 
hydrated electrons can initiate reductive activation of the prodrugs under hypoxic conditions. 
 
We have reported that galvanostatic electrolysis or radiation-induced oxidation of aqueous 5-FU 
solution yields the N1–C5′-linked dimer hydrate of 5-FU (1) via head-to-tail coupling between the N1-
centered radical and C5′-centered radical of 5-FU (Figure 2) [30, 31]. An interesting finding is that the 
N1-C5′-dimer hydrate 1 undergoes radiation-induced reduction under anaerobic conditions and 
releases the parent 5-FU with a 16% yield (Figure 3). Radiolysis of the dimer hydrate 1 under N2O-
saturated conditions, where the primary species of hydrated electrons are scavenged by N2O, induced 
no such release of 5-FU, suggesting the reductive splitting of the dimer 1 is operative under anaerobic 
irradiation. To evaluate the relationship between the molecular structure and the reactivity of the one-






N2O eaq-+ N2 OHOH+ +
Scheme 1. Primary water radicals generated from water radiolysis. 
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electron reductive release of 5-FU in anoxic aqueous solution, a series of 5-fluoro-1-(2′-
oxocycloalkyl)uracils (2–10) were synthesized (Figure 4) [39].  








































8: R = CH3
9: R = t-Bu (cis)
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All the 5-FU derivatives 2-10 bearing the 2′-oxo group underwent one-electron reduction by the 
addition of eaq– and thereby released 5-FU in sufficient yields of 47-96% upon radiolysis of the anoxic 
aqueous solution. Release of fluoride ion from the 5-FU derivatives was not observed during the 
radiolysis suggesting that eaq– is captured primarily by the 2’-oxo group. In fact, the control 
compounds without the 2′-oxo substituent (11, 12) had no reactivity toward such a reductive C1′-N1 
bond splitting. Comparing the reactivities of the stereoisomeric derivatives 9 and 10 showed that the 
efficiency of 5-FU release was strongly dependent on their structural flexibility. X-ray crystallographic 
studies of representative compounds revealed that the C1′-N1 bond possesses normal geometry and 
bond length in the ground state. Molecular orbital (MO) calculations by the AM1 method for 
optimized structures demonstrated that the lowest unoccupied molecular orbital (LUMO) is localized 
primarily at the π* orbital of the C5–C6 double bond of the 5-FU moiety and that the LUMO + 1 is 
delocalized between the π* orbital of the 2′-oxo substituent and the σ* orbital of the adjacent C1′–N1 
bond (Figure 5). It is presumable that the one-electron reductive release of 5-FU in anoxic aqueous 
solution occurs from the LUMO + 1 of the radical anion intermediates possessing a partial mixing of 
the antibonding C(2′)=O π* and C1′–N1 σ* MOs, and that dynamic conformational changes may 
achieve a higher degree of (π* + σ*) MO mixing. 
 
Figure 5. Proposed mechanism for reductive release of 5-FU from 2-7. 
 
Based on these observations, our group has developed the simplest prototypes of the 5-FU prodrugs 
13, and we have investigated the radiation chemical reactivity, biological effects, in vivo efficacy, 
pharmacokinetics, and toxicity [40, 41]. The prodrug 13 dissolved in phosphate buffer released 5-FU 
with a G-value (mol number of molecules that are decomposed or produced by 1 J of absorbed 
radiation energy) of 1.9 × 10–7 mol/ J (26%, based on total amount of primary species generated from 
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The G-value for 5-FU release was 1.0 × 10−8 mol/J following aerobic irradiation. Adding 
hypoxically irradiated (7.5–30 Gy) 13 to murine SCCVII cells for 1–24 h showed a significant 
cytotoxic effect. In contrast, cytotoxicity was minimal in cells treated with aerobically irradiated or 
unirradiated 13. This compound had no radiosensitizing effect against SCCVII cells under either 
aerobic or hypoxic conditions when the drug was removed immediately after irradiation. Following 
administration of 13 and irradiation at 30 Gy, the average 5-FU levels in the tumor and serum were 
179ng/g and 83ng/mL, respectively. However, a TCD-50 tumor growth delay assay of 13 
demonstrated an enhancement ratio of only 1.2. We recently synthesized a similar family of radiation-
activated prodrug of 5-FdUrd [42], which is generally more toxic than 5-FU [43]. 5-FdUrd derivatives 
14-18 possessing a 2-oxoalkyl group at the N3 position were synthesized, and their radiolytic one-
electron reduction product was characterized (Figure 6).  
 










The prodrugs released 5-FdUrd efficiently upon hypoxic irradiation by reacting with eaq– as in the 
case of 5-FU. A biological assay using P388 T cells and EMT6/KU cells revealed that hypoxic X-
irradiation enhanced cytotoxicity of the prodrugs dramatically. However, we observed no marked 
effects in vivo even when 100 or 300 mg/kg of 16 was combined with 20 Gy of irradiation [44]. 
Although the in vivo effect of both prodrugs of 5-FU and 5-FdUrd was not enough for clinical efficacy, 
this prototype agent suggests that radiation-activated prodrugs exhibit a certain level of cytotoxicity 
toward hypoxic tumor cells. As an extension of our work on the development of radiation-activated 
antitumor prodrugs, we designed another 5-FdUrd prodrug possessing indolequinone structure 19 
(Figure 7) [45]. Indolequinone has the following unique reaction characteristics [46-49]. First, both 
enzymatic reduction and radiolytic reduction can activate this substituent. Second, the reductive 
activation of indolequinone derivatives to release drugs is accompanied by the concomitant formation 
of electrophilic iminium cations like 20, which may invoke DNA alkylation or other cellular damage 
[50]. In view of these reaction characteristics, a 5-FdUrd prodrug possessing an indolequinone 
structural unit may result in synergic cytotoxicity that originates from both the parent drug and 
electrophilic iminium species released upon radiolytic reduction and bioreduction in hypoxic cells. 
Hypoxic irradiation of 19 significantly increased the cytotoxicity against hypoxic tumor cells and 
caused higher cytotoxicity toward EMT6/KU cells than did the hypoxic irradiation with the original 5-
FdUrd alone. Our group is currently investigating the in vivo effect of 19. 
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Photoactivatable 5-FU Prodrugs 
 
Much research effort has focused on the development of antitumor prodrugs with functions that are 
activated upon controlled photoirradiation [51]. One general strategy to achieve photoinduced 
activation of the prodrugs is the initial deactivation of a parent drug by introduction of a photolabile 
protecting group at a critical position to reduce the cytotoxicity of the chemically modified parent drug 
under unirradiated conditions. Under photoirradiation with appropriate wavelength, the photolabile 
protecting group is removed from the prodrug constitution to release a parent drug, which regenerates 
the original cytotoxicity. Various photoactivated prodrugs with effective photolabile protecting groups 
(e.g., o-nitrobenzyl chromophores, 3,5-dimethoxybenzoin derivatives, and coumarin derivatives) have 
been developed that can be activated efficiently by irradiation with UV-A (320-400 nm) or visible 
light to release the parent drugs, including phosphoramidite mustard [52], L-leucyl-L-leucine methyl 
ester [53,54], aspirin [55,56], cyclic enediyne [57], and paclitaxel [58,59]. Photoactivated prodrugs can 
be applied in surface cancer treatment and can even be adapted for deep-seated cancer therapy 
employing endoscopes or optical fibers, as used in photodynamic therapy. 
Among the various photosensitive protective groups, o-nitrobenzyl chromophore [60] is used most 
commonly for providing photoactivated prodrugs. o-Nitrobenzyl is a general photosensitive protective 
group for various chemical functionalities, such as alcohols, aldehydes, carboxylic acids, amines, and 
phosphates. Pei and Gong reported recently on a 5-FdUrd prodrug possessing the photolabile 4,5-
dimethoxy-2-nitrobenzyl group 21 (Figure 8) [61]. They demonstrated the efficient photoinduced 
release of 5-FdUrd and 4,5-dimethoxy-2-nitrosobenzaldehyde via a spontaneous decarboxylation 
reaction from the prodrug 21 by first-order kinetics with a t1/2 = 6 min. They also showed inhibition of 
cell growth by photoirradiation. Without photoirradiation, prodrug 21 only slightly inhibited growth, 
whereas cell growth was inhibited completely when the cell culture containing prodrug 21 was 
irradiated with a 350 nm lamp.  
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We recently designed a photoactivated prodrug of 5-FU conjugated with a tumor-homing cyclic 
peptide to generate the first prototype compound of a tumor-targeting photoactivated antitumor 
prodrug 23 (Figure 9) [62]. The tumor vasculature is morphologically abnormal and carries various 
types of tumor molecular markers that can be used to discriminate tumor vessels from the normal 
vasculature. We employed chemical conjugation of a 5-FU prodrug possessing an o-nitrobenzyl group 
with cyclic peptide Cys-Asn-Gly-Arg-Cys (CNGRC), which should target one of the tumor molecular 
markers, a specific APN/CD13 aminopeptidase N. Photoirradiation of the photoactivated prodrug 23 
readily removed the photolabile o-nitrobenzyl chromophore to give quantitative amounts of 5-FU, 
whereas the prodrug was quite stable under dark conditions. We also clarified the photoactivation 
mechanism of the simple model compound 22 using nanosecond laser flash photolysis studies. 
Although the in vitro and in vivo evaluation is in progress, the prodrug 23 is expected to show selective 
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Lin and coworkers reported another example of a photoactivated prodrug containing 5-fluoro-1-
(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione (tegafur/Ftorafur) 24 (Figure 10) [63]. Tegafur, an 
orally active prodrug of 5-FU, is used widely in the treatment of gastrointestinal malignancies and has 
modest efficacy [64]. Upon photoirradiation at 350 nm, the tegafur prodrug incorporating a 
triphenylporphyrin and photolabile o-nitrobenzyl group is converted into the anticancer drug tegafur 
with the photochemical quantum yield Φ = 0.032. An MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl-tetrazolium bromide] assay demonstrated that the porphyrin–nitrobenzene–tegafur conjugate 
shows photoinduced cytotoxicity for MCF-7 mammary cancer cells because of the efficient release of 
tegafur upon photoirradiation at 350 nm, whereas the prodrug 24 is significantly less toxic than its 
parent anticancer drug tegafur in the absence of UV irradiation.  
 













Other interesting examples have been reported. Agarwal and coworkers demonstrated a 
photoinduced 5-FU release system from methylcoumarin end-functionalized acrylic polymer 
conjugated with the prodrug 1-heptanoyl-5-fluorouracil (H5FU), which was developed for intraocular 
lenses equipped with a multidose drug depot used in cataract surgery (Figure 11) [65]. The coumarin-
functionalized polymer-H5FU conjugate 25 was synthesized photochemically via a [2+2] 
cycloaddition reaction between the C3-C4 double bond of methylcoumarin and the C5-C6 double bond 
of H5FU upon photoirradiation at 350 nm. In contrast to the [2+2] cycloaddition reaction, the [2+2] 
cycloreversion reaction on the cyclobutane ring proceeds under photoirradiation using a shorter 
wavelength. Consequently, photoirradiation of 25 at 266 nm induces the cleavage of the cyclobutane 
linker between the methylcoumarin moiety and the prodrug H5FU, leading to the efficient release of 
H5FU. Subsequent hydrolysis of H5FU in aqueous solution produces 4.76 μg of 5-FU from 1 mg of 
the polymer–drug conjugate 25 after photoirradiation for 150 min, indicating that LD50 of 5-FU for 
rabbit lens epithelial cells can be realized even with small amounts of polymer-drug conjugate 25, 
although the photoinduced drug release system has not been evaluated in vitro and in vivo. Further 
studies to avoid the risk of DNA being damaged by UV-C radiation would be necessary for its clinical 
use. 
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Figure 11. Photo-induced drug release from coumarin-functionalized polymer-H5FU 




In the past decade, varieties of photoremovable protecting groups have been developed to control 
the activity of small molecules, including bioimaging molecules and several kinds of pharmaceutical 
drugs, by irradiating them with light of specific wavelength and intensity. On the other hand, the 
ionizing radiation-activated system is not ideal for diagnostic use in the medical field but should be 
applicable to activating antitumor drugs for sensitizing the drugs to increase the cytotoxic effect of 
ionizing radiation. In this review, we have summarized the properties of 5-FU prodrugs, which are 
radiation-chemically or photochemically activatable under the microenvironment of tumor cells. 
Irradiated prodrugs have high cytotoxicity that is dependent on both the drug contact time and 
radiation dose, whereas unirradiated prodrugs show minimal cytotoxicity against tumor cells. 
Disappointingly, the effects of these prototypes, including N1- or N3-(2′-oxoalkyl)-5-FU derivatives, 
are not strong enough for clinical efficacy, partly due to low efficiency (26% or less) of 5-FU-release 
from the prodrugs. Although there is limit in clinically permitted does of radiation, we expect that 
further research on the synthesis and evaluation of more potent anticancer drugs bearing both 5-FU 
and alkylating agents, such as indolequinone derivatives, will lead to the development of more 
promising prodrugs that are activatable by external signals. 
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